Physiology‐based pharmacokinetic modelling and experimental data suggest that rifabutin alters dolutegravir kinetics by both P‐glycoprotein induction and concurrent inhibition

Low-Dose Rifabutin Increases Cytotoxicity in Antimitotic-Drug-Treated Resistant Cancer Cells by Exhibiting Strong P-gp-Inhibitory Activity

(2022) Ji Sun Lee et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Drug–drug interaction between rifabutin and dolutegravir: A population pharmacokinetic model

(2022) Aida N. Kawuma et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

In vitro evidence suggesting that the toll-like receptor 7 and 8 agonist resiquimod (R-848) unlikely affects drug levels of co-administered compounds

(2021) Dirk Theile et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin

(2012) Kelly E. Dooley et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Transporter-Mediated Drug–Drug Interactions

(2011) L Zhang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A regulatory viewpoint on transporter-based drug interactions

(2008) L. Zhang et al.   XENOBIOTICA